Docetaxel: An Update of its Use in Advanced Breast Cancer

Figgitt, D.P.; Wiseman, L.R.
March 2000
Drugs;Mar2000, Vol. 59 Issue 3, p621
Academic Journal
Docetaxel, a semisynthetic member of the taxoid class of antineoplastic agents, is effective in the treatment of patients with advanced (locally advanced or metastatic) breast cancer. Reported objective response rates for docetaxel 100 mg/m ranged from 54 to 69% and 53 to 82% as first-line monotherapy or combination therapy, respectively. Objective response rates of 23 to 65% and 30 to 81% have been reported for docetaxel as second-line monotherapy or combination therapy, respectively. In Japanese studies, second-line docetaxel 60 mg/m produced objective response rates of 42 to 55%. At the recommended dose of 100 mg/m given as a 1-hour intravenous (IV) infusion every 3 weeks, docetaxel had significantly greater efficacy than doxorubicin, mitomycin plus vinblastine and methotrexate plus fluorouracil, and similar efficacy to fluorouracil plus vinorelbine in pretreated patients with advanced breast cancer. In chemotherapy-naive patients, first-line combined therapy with docetaxel and doxorubicin had significantly greater efficacy than doxorubicin plus cyclophosphamide. Promising results have been achieved in phase I/II trials of a weekly regimen of docetaxel (generally 30 to 45 mg/m). Preliminary data indicate a potential role for docetaxel in the neoadjuvant therapy of early breast cancer. The major dose-limiting adverse event associated with docetaxel is neutropenia. Although other adverse events are common, the tolerability profile of docetaxel is generally acceptable in the majority of patients, particularly in comparison with other antineoplastic regimens. Conclusions: Although no single standard regimen has been identified as optimal for the treatment of advanced breast cancer, phase III trials have shown that docetaxel has improved efficacy over doxorubicin alone (considered one of the current gold standards), methotrexate/fluorouracil and mitomycin/vinblastine in second-line therapy. In combination with doxorubicin, docetaxel has demonstrated better efficacy than doxorubicin/cyclophosphamide in first-line therapy. These results provide a basis for therapy choice in advanced breast cancer. Clinical trials comparing docetaxel monotherapy versus paclitaxel monotherapy and versus docetaxel combination therapy are warranted. The role of docetaxel in the adjuvant and neoadjuvant treatment of early breast cancer is being evaluated.


Related Articles

  • docetaxel.  // Davis's Drug Guide for Nurses, 10th edition;2007, p413 

    The article presents a nursing guide to docetaxel, an antineoplastic agent for the treatment of breast cancer, advanced metastatic hormone-refractory prostate cancer, among others. Its mechanism of action and pharmacokinetics are explained. Contraindications for the drug are presented. Its...

  • Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Radaideh, Sofyan M.; Sledge, George W. // Breast Cancer Research & Treatment;Sep2008, Vol. 111 Issue 2, p203 

    Taxanes (paclitaxel and docetaxel) comprise a class of mitotic inhibitors which considered highly active chemotherapeutic agents against cancer cells, and have become a cornerstone in the treatment of patients with early and advanced breast cancer. Following the initial generation of trials...

  • Docetaxel Offers a More Effective but More Toxic Drug Regiment for Breast Cancer. Hayasaka, Elana // JNCI: Journal of the National Cancer Institute;7/6/2005, Vol. 97 Issue 13, p957 

    Cites key research findings in 2005 indicating that a combination of the taxane docetaxel with doxorubicin and cyclophosphamide may be a more effective adjuvant treatment for breast cancer.

  • Aventis: Taxotere competes for bigger share in the breast cancer market.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p4 

    Reports on the results of a clinical trial in the United States comparing Aventis Inc.'s Taxotere (docetaxel) and Taxol (paclitaxel) of Bristol-Myers Squibb Co. for the treatment of breast cancer. Better overall response rate of Taxotere; Drug toxicity; Aventis' effort to gain approval for...

  • Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer. Medioni, Jacques; Huchon, Cyrille; Frere-Belda, Marie-Aude Le; Hofmann, Henri; Bats, Anne-Sophie; Eme, Denise; Andrieu, Jean-Marie; Oudard, St├ęphane; Lecuru, Fabrice; Levy, Eric // Drugs in R&D;2011, Vol. 11 Issue 2, p147 

    Background: Neoadjuvant anti-tumor activity of an alternating taxane- and anthracycline-based dose-dense regimen in patients with operable, noninflammatory large breast cancer was investigated. Objective: The objective is to study the rate of pathological complete response in patients with...

  • Docetaxel of value for metastatic breast cancer.  // PharmacoEconomics & Outcomes News;5/3/2008, Issue 552, p3 

    The article discusses research on survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer. It references a study by T. Vu published in the Marc 2008 issue of "Annals of Oncology." A significantly reduced risk of death was demonstrated by...

  • Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Stathopoulos, G. P.; Tsavdaridis, D.; Malamos, N. A.; Rigatos, S. K.; Kosmas, Ch.; Pergantas, N.; Stathopoulos, J. G.; Xynotroulas, J. // Cancer Chemotherapy & Pharmacology;Nov2005, Vol. 56 Issue 5, p487 

    Purpose: This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively.Methods: Forty-eight (median age 54...

  • Docetaxel.  // Reactions Weekly;11/5/2011, Issue 1376, p13 

    The article describes several cases of female patients with breast cancer who developed cicatricial entropion and structural eyelash abnormalities while undergoing docetaxel therapy. One of the patients, a 54-year-old woman, experienced diffuse lash misdirection, blepharitis and meibomianitis on...

  • Phase I Trial of Dose-Dense Docetaxel and Doxorubicin with or without Sargramostim in Patients with Metastatic Breast Cancer. Montero, Alberto; Booser, Daniel; Esparza-Guerra, Laura; Murray, James; Rosales, Marguerite; Hortobagyi, Gabriel; Valero, Vicente // Drugs in R&D;2005, Vol. 6 Issue 5, p299 

    Focuses on the phase I clinical trial on the combiantion of dose-dense docetaxel and doxorubicin antineoplastic agents with or without Sargramostim treating patients with metastatic breast cancer. Rate of progression of metastatic breast cancer following treatment of the combined antineoplastic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics